ResearcherActive in the last 2 years

Susumu Kitanaka

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5113824826. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Apoptosis Induction by 3EE, 20Ac-Ingenol in p53- and K-RAS-Mutated Pancreatic Cancer, Panc-1 Cells Overexpressing Cyclin D1 Through Cdk2/E2F1 and ARF Activation Last author DOI 10.20944/preprints202607.0151.v1 ↗
Ingenol mebutate inhibits the growth of pancreatic cancer cells in vitro via STING with an efficacy comparable to that of clinically used anticancer agents. Co-author DOI 10.1007/s11418-023-01682-1 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shohei Miyata · 1 shared paper, 2026 · strength 0.39
- Paper Apoptosis Induction by 3EE, 20Ac-Ingenol in p53- and K-RAS-Mutated Pancreatic Cancer, Panc-1 Cells Overexpressing Cycli… DOI 10.20944/preprints202607.0151.v1 ↗
Tomonori Nakamura · 1 shared paper, 2023 · strength 0.20
- Paper Ingenol mebutate inhibits the growth of pancreatic cancer cells in vitro via STING with an efficacy comparable to that … DOI 10.1007/s11418-023-01682-1 ↗
Fumihiro Kikuyama · 1 shared paper, 2023 · strength 0.20
- Paper Ingenol mebutate inhibits the growth of pancreatic cancer cells in vitro via STING with an efficacy comparable to that … DOI 10.1007/s11418-023-01682-1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.